Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion.
Kattamis
Antonis
A
Kassou
Christina
C
Berdousi
Helen
H
Ladis
Vasilis
V
Papassotiriou
Ioannis
I
Kattamis
Christos
C
D000293:Adolescent; D000328:Adult; D015913:Chelation Therapy; D003131:Combined Modality Therapy; D000077543:Deferiprone; D003676:Deferoxamine / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007501:Iron / Q000652:urine*; D007502:Iron Chelating Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D019190:Iron Overload / Q000188:drug therapy* / Q000209:etiology / Q000652:urine; D008297:Male; D011728:Pyridones / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D013156:Splenectomy; D014018:Tissue Distribution; D065227:Transfusion Reaction; D016896:Treatment Outcome; D017086:beta-Thalassemia / Q000601:surgery / Q000628:therapy / Q000652:urine*
D007502:Iron Chelating Agents; D011728:Pyridones; D000077543:Deferiprone; D007501:Iron; D003676:Deferoxamine